Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single-center, Open-label, Randomized, Two-way Crossover Study in Healthy Adult Male Subjects to Compare the Pharmacokinetics of Selexipag (ACT-293987) Following Single Oral Administration of 4 Film-coated Pediatric Tablets of 50 µg vs One Film-coated Tablet of 200 µg Selexipag

Next Previous
Trial Profile

Single-center, Open-label, Randomized, Two-way Crossover Study in Healthy Adult Male Subjects to Compare the Pharmacokinetics of Selexipag (ACT-293987) Following Single Oral Administration of 4 Film-coated Pediatric Tablets of 50 µg vs One Film-coated Tablet of 200 µg Selexipag

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Selexipag (Primary)
  • Indications Arteriosclerosis obliterans; Pulmonary arterial hypertension; Pulmonary hypertension; Raynaud's disease
  • Focus Pharmacokinetics
  • Sponsors Actelion Pharmaceuticals

Most Recent Events

  • 27 Jun 2017 Primary endpoint (Maximum plasma concentration (Cmax) of selexipag) has not been met as per the results presented at the 13th Congress of the European Association for Clinical Pharmacology and Therapeutics
  • 27 Jun 2017 Primary endpoint (Maximum plasma concentration (Cmax) of ACT-333679) has been met as per the results presented at the 13th Congress of the European Association for Clinical Pharmacology and Therapeutics
  • 27 Jun 2017 Primary endpoint (Area under plasma concentration-time curve [AUC(0-inf)] of selexipag and ACT-333679) has been met as per the results presented at the 13th Congress of the European Association for Clinical Pharmacology and Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top